Friday, November 17, 2017

Syapse Gets $30M For Precision Oncology Efforts

San Francisco-based Syapse, a developer of precision medicine products, said earlier this week that it has raised $30M in a Series D funding round. The funding came from Ascension Ventures, GE Ventures, Intermountain Healthcare Innovation Fund, Safeguard Scientifics, and Social Capital, plus new investors Amgen Ventures, Medidata Solutions, Merck Global Health Innovation Fund, and Roche Venture Fund. Syapse, led by CEO Ken Tarkoff, said it is developing precision oncology software which allows oncologists to view treatments and outcomes for patients of other oncologists across the country, to help improve their own treatment decisions. More information »